<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04563832</url>
  </required_header>
  <id_info>
    <org_study_id>APHP2020</org_study_id>
    <nct_id>NCT04563832</nct_id>
  </id_info>
  <brief_title>Self-administered Hyperinsufflation Chest on the Risk of Low Respiratory Infection in Patients With Multiple Sclerosis With Sputum Capacity Deficit</brief_title>
  <acronym>MS-COUGH</acronym>
  <official_title>Self-administered Hyperinsufflation Chest Mobilization Randomized Study on the Risk of Low Respiratory Infection in Patients With Multiple Sclerosis With Sputum Capacity Deficit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with neuromuscular disease, chest mobilization by hyperinsufflation slows&#xD;
      respiratory decline by almost 80% compared to controls, and prevents complications like&#xD;
      pneumonia, atelectasis and respiratory distress.&#xD;
&#xD;
      This insufflation technique improves the airway clearance and reduces the need for invasive&#xD;
      ventilation. It also improves CV and DEPtoux in patients with neuromuscular pathology&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During multiple sclerosis (MS), although expiratory involvement and reduced sputum capacity&#xD;
      are predominant, automated techniques of hyperinsufflation and in-exsufflation remain&#xD;
      underused and undervalued. A single retrospective study suggests a decrease in the decline in&#xD;
      respiratory function with regular manual hyperinsufflation.&#xD;
&#xD;
      Evidence of a benefit of chest mobilization by hyperinsufflation by a controlled trial is&#xD;
      therefore necessary before recommending its use in MS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Control group: standardized respiratory management.&#xD;
Experimental group: same program, associated with the daily use of a hyperinsufflation technique.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of a self-administered automated hyperinsufflation technique for 2 years, versus standard management, on respiratory infection risk within 2 years after randomization, in patients with MS.</measure>
    <time_frame>24 months</time_frame>
    <description>This will be evaluated by the incidence of lower respiratory infections requiring antibiotic therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of COUGH-ASSIST on slowing the decline in respiratory function,</measure>
    <time_frame>12 months and 24 months</time_frame>
    <description>This will be demonstrated by monitoring respiratory function by spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional effectiveness of COUGH-ASSIST</measure>
    <time_frame>12 months and 24 months</time_frame>
    <description>By using the goal attainmentscaling method (GAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance and compliance with COUGH-ASSIST,</measure>
    <time_frame>24 months</time_frame>
    <description>This will be evaluated via an online &quot;patient reported outcomes form&quot; and data readings from the internal memory of the COUGH-ASSIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of COUGH-ASSIST in reducing the risk of serious respiratory infection</measure>
    <time_frame>24 months</time_frame>
    <description>This will be evaluate by the number of serious respiratory infection</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>standardized respiratory management.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>same program as control group associated with the daily use of a hyperinsufflation technique (2 times per day during15 minutes, 5 days a week, for 2 years)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standardized respiratory management program</intervention_name>
    <description>Bronchial decluttering education, respiratory physiotherapy, specialized medical follow-up for 2 years</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CoughAssist</intervention_name>
    <description>self-administered mechanical in-exsufflation - CoughAssist (2 x 15 min per day, 5 days per week for 2 years)</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed MS diagnosis (McDonald criteria)&#xD;
&#xD;
          -  EDSS ≥ 7&#xD;
&#xD;
          -  Age greater than or equal to 18 years.&#xD;
&#xD;
          -  Expiratory flow during a coughing effort (DEPtoux) ˂4.5L / s.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ENT and / or thoracic surgery less than 6 months old&#xD;
&#xD;
          -  Progressive or past pneumothorax / pneumomediastinum&#xD;
&#xD;
          -  Severe swallowing disorders.&#xD;
&#xD;
          -  Inability to use the device under study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jonathan LEVY, Dr</last_name>
    <phone>+33 147107900</phone>
    <email>jonathan.levy2@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hélène PRIGENT, Pr</last_name>
    <phone>+33 147107900</phone>
    <email>helene.prigent@aphp.fr</email>
  </overall_contact_backup>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 21, 2020</study_first_submitted>
  <study_first_submitted_qc>September 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2020</study_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

